London, UK and Carlsbad, CA, USA, April 13, 2018 / B3C newswire / -- DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections that can lead to sepsis, announces that new data will be presented on its LiDia® Bloodstream Infection (BSI) test(1)(2) at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Madrid, Spain, 21-24th April, 2018.
A demonstration of the blood-to-result workflow for LiDia® BSI will be previewed at DNAe’s booth at ECCMID.
Dr Steve Allen, CEO of DNAe Group Holdings, commented: “ECCMID comes at a pivotal time in our journey to bring this vital rapid diagnostic test to market. We are pleased to present key data and look forward to reaching more of the infectious disease community at the event this year. The congress gives us an excellent opportunity to showcase the LiDia® BSI closed cartridge-based test for the first time to a wide clinical audience at our stand, and to demonstrate its potential to support faster and more informed treatment of sepsis.”
Details of the poster presentation are as follows:
Poster Presentation – #P1960
Title: Rapid Detection of Clinically-Confirmed Bloodstream Pathogens in Culture-Negative Specimens'
Time and Date: 12:30 pm - 1:30 pm CEST, Tuesday, 24th April
Session: Diagnostic Approaches in Bacterial Bloodstream Infection
Location: Paper Poster Arena
The abstract is available online, here.
LiDia® BSI Demonstrations
Demonstrations will take place at DNAe’s booth between the following times:
12:00 noon – 6 pm CEST, Saturday, 21st April
9.30 am – 5 pm CEST, Sunday, 22nd April
9.30 am – 5 pm CEST, Monday, 23rd April
9.30 am – 2 pm CEST, Tuesday, 24th April
Location: Booth #104
If you would like to reserve a demonstration timeslot please RSVP in advance online, here.
Operating as a closed cartridge-based test, LiDia® BSI utilizes highly sensitive sample preparation and semiconductor-based PCR analysis to rapidly identify pathogens and key antibiotic resistance markers. Aiming to deliver clinically actionable results straight from raw blood specimens in under 3 hours, LiDia® BSI will aid patient management by offering a significant reduction in time-to-result compared to the current standard of culture-based diagnosis, which generally requires several days to produce a result.
DNAe is developing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.
In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia®, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia® range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.
DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia® will launch with the LiDia® Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.
A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.
Dr Steve Allen, Chief Executive Officer, DNAe Group
+44 (0)20 7036 2100
Instinctif Partners (media relations)
Sue Charles / Ashley Tapp / Alex Bannister
+44 (0)20 7457 2020
(1) Test in development. For Research Use Only. Not for use in diagnostic procedures
(2) This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201400015C.